Get the Stockscreener App
0.8799
2.22%
-0.02
Ocean Biomedical Inc stock is traded at $0.8799, with a volume of 16,002.
It is down -2.22% in the last 24 hours and down -3.42% over the past month.
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
See More
Previous Close:
$0.8999
Open:
$0.899
24h Volume:
16,002
Relative Volume:
0.31
Market Cap:
$31.18M
Revenue:
-
Net Income/Loss:
$-82.19M
P/E Ratio:
-0.2292
EPS:
-3.839
Net Cash Flow:
$-8.35M
1W Performance:
-4.36%
1M Performance:
-3.42%
6M Performance:
-40.14%
1Y Performance:
-48.54%
1-Day Range:
$0.86
$0.8999
1-Week Range:
$0.8301
$0.92
52-Week Range:
$0.52
$7.79
Ocean Biomedical Inc Stock (OCEA) Company Profile
Name
Ocean Biomedical Inc
Sector
Industry
Phone
(646) 908-2658
Address
515 MADISON AVE SUITE 8078, NEW YORK
Ocean Biomedical Inc Stock (OCEA) Latest News
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Curis (CRIS) Stock Plummets Over 5% Amid Lack of Institutional R - GuruFocus.com
Ocean Biomedical appoints interim CEO amid executive shift - Investing.com India
Ocean Biomedical appoints interim CEO amid executive shift By Investing.com - Investing.com South Africa
Ocean Biomedical receives Nasdaq’s delisting letter - MSN
Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services - The Manila Times
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter - GlobeNewswire
Taipei showcases cutting-edge medical devices & diagnostics at Medica 2024 - healthcare-in-europe.com
Ocean Biomedical secures 22% Virion stake with $9 million deal - Investing.com India
Ocean Biomedical secures 22% Virion stake with $9 million deal By Investing.com - Investing.com South Africa
Molecure inks $32 million deal with Ocean Biomedical for cancer therapy - Investing.com India
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. - The Manila Times
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company - GlobeNewswire
Molecure S.A. and Ocean Biomedical Inc. Sign an Exclusive Licensing Agreement for the Development and Commercialization of Selective YKL-40 inhibitors - Marketscreener.com
CAE Inc. (CAE): An Undervalued Foreign Stock to Buy According to Analysts - Yahoo Finance UK
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of September 2024 - EIN News
Casella Waste Systems, Inc. to Host Conference Call on Its Third Quarter 2024 Results - EIN News
Kaltura to Announce Financial Results for Third Quarter 2024 on Wednesday, November 6, 2024 - EIN News
Shareholders of Outset Medical, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your - EIN News
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for Investors – Contact Levi & - EIN News
DOMINO’S PIZZA, INC. (NYSE: DPZ) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Domino’s Pizza, Inc. Investors - EIN News
BioPhotonics Conference 2024 - Photonics Spectra
Ocean Outdoor (LON:OOUT) Trading Up 0.7% - Defense World
Angry Bank of America customers report outages, zero account balances across the country - Yahoo News Canada
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - The Manila Times
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication - GlobeNewswire
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses - GlobeNewswire Inc.
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses - GlobeNewswire
Ocean Biomedical, Inc. (NASDAQ:OCEAW) Short Interest Update - Defense World
Fralin Biomedical Institute Award Supports Innovation in Brain Cancer Treatment - The Roanoke Star
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement - Yahoo Finance UK
IPO News: Everything you need to know about BioAge Labs’ IPO - AlphaStreet
OceanFirst Financial (NASDAQ:OCFC) Hits New 52-Week High at $18.97 - MarketBeat
Delisting of Securities of OceanTech Acquisitions I Corp.; OCA Acquisition Corp.; Assure Holdings Corp.; Selina Hospitality PLC; Maquia Capital Acquisition Corporation; ToughBuilt Industries, Inc.; SunPower Corporation; Meta Materials Inc.; Talis Biomedical - StockTitan
What's Going On With Odyssey Marine Exploration Stock? - Benzinga
OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
OM CLASS ACTION: Outset Medical, Inc. Stockholders Should - GlobeNewswire
OM CLASS ACTION: Outset Medical, Inc. Stockholders Should Contact Robbins LLP for Information - The Bakersfield Californian
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Gaining Ground: Outset Medical Inc (OM) Closes Lower at 0.52, Down -1.34 - The Dwinnex
Pret A Manger annual sales surge past £1bn but growth slows in 2024 - Yahoo Finance UK
Ocean Power Technologies Stock Climbs On Q1 Results: Details - Benzinga
Oceaneering International, Inc. [OII] stock was sold by Beachy Karen H at the price of US$75702.0 - Knox Daily
I’d drip-feed £458 a month into a Stocks and Shares ISA to try for a million - Yahoo Finance UK
If I could pick just one passive income stock from the FTSE ever, this would be it - Yahoo Finance UK
Outset Medical (OM) Shares Down 94% Since Disclosing FDA Warning Letter, Class Action Pending – Hagens Berman - ForexTV.com
Lawsuit Notice: Investors who lost money with shares of Outset - openPR
Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight - The Malaysian Reserve
Ocean Biomedical Inc Stock (OCEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):